Advertisement

The effect of methadone on blood glucose, lipids and glucose-modulating hormones in methadone-dependent Wistar rats

  • Zoya TahergorabiEmail author
  • Hadiseh Rahmani
  • June Williams
  • Mitra Moodi
Original Article

Abstract

A growing body of evidence indicates that opioids regulate mechanisms activated during the stress response. This study was aimed to investigate the effect of methadone dependency on blood glucose, lipids and glucose-modulating hormones in male and female Wistar rats.This study was performed on 40 Wistar rats weighing 150–350 g, in four methadone exposure and control groups of both males and females. All rats were weighed at the beginning and end of the study and their fasting blood glucose was measured using a glucometer. In order to induce addiction, methadone was injected intraperitoneal for 10 consecutive days at 5 mg/kg dose. The control group received the same volume of only normal saline. At the end of the study, the rats were sacrificed and their blood serum collected to measure cortisol, glucagon, adrenaline and lipid profile levels.There was a significant decrease in the mean final blood glucose of methadone-treated versus control male rats (p = 0.02). There was no significant glucose difference, however, in female rats. Furthermore, a decrease in the mean serum levels of triglyceride, cortisol, and adrenaline occurred in male rats of methadone-dependent compared with control animals, but there was no significant difference in these values in female rats. Our results showed that methadone significantly reduced serum glucose as well as triglyceride levels only in male rats, this being associated with a reduction in the level of counter-regulating hormones of carbohydrate metabolism. Changes in lipid profiles, however, occurred independently of gender.

Keywords

Methadone Glucose-modulating hormones Wistar rats Blood glucose 

Abbreviations

ACTH

Adrenocorticotropic hormone

CNS

Central nervous system

CRH

Corticotrophin releasing hormone

FSH

Follicular stimulating hormone

HCV

Hepatitis C virus

HBV

Hepatitis B virus

HPA

Hypothalamic-hypophysial-adrenal

HDL

High density lipoprotein

LDL

Low density lipoprotein

LH

Luteinizing hormone

MMT

Methadone maintenance treatment

SD

Standard deviation

UNODC

The United Nations’ Office on Drugs and Crime

Notes

Acknowledgements

The authors would like to thank the Vice Chancellor for the Research and Technology of the Birjand University of Medical Sciences for funding this study (the research Project No. 455381.)

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to disclose.

References

  1. 1.
    Chen C-Y, Lin K-M (2009) Health consequences of illegal drug use. Curr Opin Psychiatry 22:287–292CrossRefGoogle Scholar
  2. 2.
    Ghane T, Zamani N, Hassanian-Moghaddam H, Beyrami A, Noroozi A (2018) Lead poisoning outbreak among opium users in the Islamic Republic of Iran, 2016–2017. Bull World Health Organ 96:165CrossRefGoogle Scholar
  3. 3.
    Najafipour H, Beik A (2016) The impact of opium consumption on blood glucose, serum lipids and blood pressure, and related mechanisms. Front Physiol 7:436CrossRefGoogle Scholar
  4. 4.
    Bozchelou S, Delirrad M (2019) Effects of methadone maintenance therapy on thyroid function of adult men. Toxicol Res 35:9–12CrossRefGoogle Scholar
  5. 5.
    Heimer R, Bray S, Burris S, Khoshnood K, Blankenship KM (2002) Structural interventions to improve opiate maintenance. Int J Drug Policy 13:101–111CrossRefGoogle Scholar
  6. 6.
    Soltaninejad K, Hassanian-Moghaddam H, Shadnia S (2014) Methadone related poisoning on the rise in Tehran. Iran. Asia Pac J Med Toxicol 3:104–109Google Scholar
  7. 7.
    Flory JH, Wiesenthal AC, Thaler HT, Koranteng L, Moryl N (2016) Methadone use and the risk of hypoglycemia for inpatients with cancer pain. J Pain Symptom Manag 51:79–87CrossRefGoogle Scholar
  8. 8.
    Toce MS, Stefater MA, Breault DT, Burns MM (2018) A case report of methadone-associated hypoglycemia in an 11-month-old male. Clin Toxicol 56:74–76CrossRefGoogle Scholar
  9. 9.
    Faskowitz AJ, Kramskiy VN, Pasternak GW (2013) Methadone-induced hypoglycemia. Cell Mol Neurobiol 33:537–542CrossRefGoogle Scholar
  10. 10.
    Moryl N, Pope J, Obbens E (2013) Hypoglycemia during rapid methadone dose escalation. J Opioid Manag 9:29–34CrossRefGoogle Scholar
  11. 11.
    Droletm G, Dumont EC, Gosselin I, Kinkead R, Laforest S, Trottier JF (2001) Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25:729–741CrossRefGoogle Scholar
  12. 12.
    Vuong C, Van Uum SH, Odell LE, Lutfy K, Friedman TC (2009) The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 31:98–132CrossRefGoogle Scholar
  13. 13.
    Karam GA, Reisi M, Kaseb AA, Khaksari M, Mohammadi A, Mahmoodi M (2004) Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. Addict Biol 9:53–58CrossRefGoogle Scholar
  14. 14.
    Karam GA, Rashidinejad HR, Aghaee MM, Ahmadi J, Rahmani MR, Mahmoodi M, Azin H, Mirzaee MR, Khaksari M (2008) Opium can differently alter blood glucose, sodium and potassium in male and female rats. Pak J Pharm Sci 21:180–184PubMedGoogle Scholar
  15. 15.
    Park SH, Sim YB, Kang YJ, Kim SM, Lee JK, Jung JS, Suh HW (2010) Characterization of blood glucose level regulation in mouse opioid withdrawal models. Neurosci Lett 476:119–122CrossRefGoogle Scholar
  16. 16.
    Pačesová D, Novotný J, Bendová Z (2016) The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in the pineal gland. Physiol Res 65:517–525PubMedGoogle Scholar
  17. 17.
    Pierce T, Hope W, Raper C (1996) The induction and quantitation of methadone dependence in the rat. J Pharmacol Toxicol Methods 36:137–146CrossRefGoogle Scholar
  18. 18.
    Fenn JM, Laurent JS, Sigmon SC (2015) Increases in body mass index following initiation of methadone treatment. J Subst Abuse Treat 51:59–63CrossRefGoogle Scholar
  19. 19.
    Kolarzyk E, Pach D, Wojtowicz B, Szpanowska-Wohn A, Szurkowska M (2005) Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przeglad lekarski 62:373–377PubMedGoogle Scholar
  20. 20.
    Kheradmand A, Banazadeh N, Abedi H (2010) Physical effects of methadone maintenance treatment from the standpoint of clients. Addict Health 2:66–73PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kolarzyk E, Chrostek Maj J, Pach D, Janik A, Kwiatkowski J, Szurkowska M (2005) Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment. Przegl Lek 62:368–372PubMedGoogle Scholar
  22. 22.
    Noor S, Alam F, Fatima SS, Khan M, Rehman R (2018) Role of Leptin and dyslipidemia in chronic kidney disease. Pak J Pharm Sci 31:893PubMedGoogle Scholar
  23. 23.
    Olszewski PK, Levine AS (2007) Central opioids and consumption of sweet tastants: when reward outweighs homeostasis. Physiol Behav 91:506–512CrossRefGoogle Scholar
  24. 24.
    Sadava D, Alonso D, Hong H, Pettit-Barrett D (1997) Effect of methadone addiction on glucose metabolism in rats. Gen Pharm Vasc Syst 28:27–29CrossRefGoogle Scholar
  25. 25.
    Santoro GC, Carrion J, Patel K, Vilchez C, Veith J, Brodie JD, Dewey SL (2017) Sex differences in regional brain glucose metabolism following opioid withdrawal and replacement. Neuropsychopharmacol 42:1841–1849CrossRefGoogle Scholar
  26. 26.
    Lin SH, Yang YK, Lee SY, Hsieh PC, Chen PS, Lu RB, Chen KC (2012) Association between cholesterol plasma levels and craving among heroin users. J Addict Med 6:287–291CrossRefGoogle Scholar
  27. 27.
    Montazerifar, F., Karajibani, M., Lashkaripour, K., Yousefi, M. (2014) Effects of methadone maintenance therapy (MMT) on serum leptin, lipid profile and anthropometric parameters in opioid addicts. Heroin Addict Relat Clin Probl 16(1):9–16Google Scholar
  28. 28.
    Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön M (2005) Plasma visfatiDn concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911–2916CrossRefGoogle Scholar
  29. 29.
    Housova J, Wilczek H, Haluzik MM, Kremen J, Krizova J, Haluzik M (2005) Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiol Res 54:73–78PubMedGoogle Scholar
  30. 30.
    Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Häring H, Stumvoll M (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243CrossRefGoogle Scholar

Copyright information

© Korean Society of Toxicology 2019

Authors and Affiliations

  • Zoya Tahergorabi
    • 1
    Email author
  • Hadiseh Rahmani
    • 2
  • June Williams
    • 3
  • Mitra Moodi
    • 4
  1. 1.Medical Toxicology and Drug Abuse Research Center (MTDRC), Department of Physiology, School of MedicineBirjand University of Medical SciencesBirjandIran
  2. 2.Committee of Student Reseach, School of MedicineBirjand University of Medical SciencesBirjandIran
  3. 3.Department of Paraclinical SciencesUniversity of PretoriaPretoriaSouth Africa
  4. 4.Social Determinants of Health Research Center, School of HealthBirjand University of Medical SciencesBirjandIran

Personalised recommendations